Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 4/20 | 0.47 |
| ▸ | RNASEH1 | O60930 | 2/20 | 0.43 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.41 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BID | P55957 | 1/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.37 |
| ▸ | SOX18 | P35713 | 1/20 | 0.37 |
| ▸ | ATP4A | P20648 | 1/20 | 0.37 |
| ▸ | ATP4B | P51164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080384 | 0.78 | KDM4E (0.46) | P2RX3KDM4EALDH1A1KMT2A | |
| SCHEMBL6080252 | 0.78 | P2RX3 (0.45) | P2RX3RNASEH1KDM4EALDH1A1KMT2A | |
| SCHEMBL6080351 | 0.78 | MAPT (0.49) | — | |
| SCHEMBL6080710 | 0.78 | CD38 (0.49) | RNASEH1KDM4E | |
| SCHEMBL6080440 | 0.77 | P2RX3 (0.44) | P2RX3RNASEH1KDM4EALDH1A1BID | |
| SCHEMBL6079750 | 0.77 | P2RX3 (0.44) | P2RX3RNASEH1KDM4EALDH1A1KMT2A | |
| SCHEMBL6080782 | 0.76 | DHODH (0.50) | RNASEH1PLAURKDM4EALDH1A1KMT2A | |
| SCHEMBL6080655 | 0.76 | ALOX5 (0.50) | P2RX3RNASEH1KDM4E | |
| SCHEMBL6080236 | 0.75 | AURKA (0.41) | P2RX3ALDH1A1 | |
| SCHEMBL6080402 | 0.75 | PARP1 (0.44) | P2RX3COPS5KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | P2RX3 465/4885RNASEH1 2268/4885PLAUR 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.